Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety Clinical Trial
Official title:
Single-arm Exploratory Clinical Study on the Second-line Treatment of Advanced Gastric Cancer With Apatinib Mesylate Plus Capecitabine
Gastric cancer is the one of the leading cause of cancer death in the worldwide. Gastric
cancer originates from the most superficial mucosal epithelial cells of the stomach wall,
which can occur in various parts of the stomach, and can invade different depths and breadth
of the gastric wall. Without chemotherapy treatment the GC patients' Median Survival Time
(MST) lasts only 3-4 months. Although treated with multi-chemotherapy MST has been improved,
the drugs show strong toxicities in the patients. Thus the more accurate, lower toxicity,
targeted antitumor drugs are put into second-line treatment program for advanced gastric
cancer.
Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor
activity in the patients with GC. The purpose of this study is to determine whether apatinib
plus capecitatine can improve progression free survival in patients with advanced gastric
cancer.
n/a